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The prevalence of life-threatening, drug-resistant microbial in-
fections has challenged researchers to consider alternatives to
currently available antibiotics. Teixobactin is a recently discov-
ered “resistance-proof” antimicrobial peptide that targets the
bacterial cell wall precursor lipid II. In doing so, teixobactin
exhibits potent antimicrobial activity against a wide range of
Gram-positive organisms. Herein we demonstrate that teixo-
bactin and several structural analogues are capable of binding
lipid II from both Gram-positive and Gram-negative bacteria.
Furthermore, we show that when combined with known outer
membrane-disrupting peptides, teixobactin is active against
Gram-negative organisms.
The growing threat of antibiotic resistance has led to the spec-
ulation that the 21st century may witness the arrival of a post-
antibiotic era in medicine, wherein antimicrobial resistance is
developing faster than before and the longevity of currently
effective antibiotics is shortened.[1] To address this growing
concern, researchers have embarked on the search for antibiot-
ics with new mechanisms of action and potential longer lasting
therapeutic lifetimes. A promising avenue lies in exploring nat-
ural products produced by microbial cultures; with particular
interest in peptides which have innate antimicrobial activity
and act upon a variety of targets due to the versatility of
amino acid building blocks.[2–4] An example of such peptide
natural product is teixobactin (Figure 1 A). This molecule was
recently uncovered using the so-called iChip technology and
found to have potent activity against a broad range of Gram-
positive organisms, including methicillin-resistant Staphylococ-
cus aureus (MRSA), vancomycin-resistant enterococci (VRE), and
Mycobacterium tuberculosis.[5] Teixobactin is a non-ribosomally
synthesized depsipeptide composed of 11 amino acids, includ-
ing four d-amino acids and the unique cyclic guanidine con-
taining amino acid l-allo-enduracididine (allo-End), a methylat-
ed N terminus, and a cyclized C terminus. In addition to these
interesting structural features, a key attraction of the molecule
was that all attempts to induce laboratory resistance in
S. aureus and M. tuberculosis strains were unsuccessful.[5] Teixo-
bactin’s activity could be extended to an Escherichia coli strain
(asmB1) with a severely damaged outer membrane.[5] Interest
in the peptide’s activity and therapeutic potential led to curios-
ity in synthetic approaches to access teixobactin; with two dis-
tinct synthetic routes reported just a year later.[6, 7] Following
the initial report, several studies were aimed at understanding
the spectrum of antimicrobial activity,[8, 9] structure–activity
studies,[10–12] interrogating the mode of action through model-
ling,[13, 14] and structural investigations.[15, 16] These studies yield-
ed insight into key residues, modifiable regions, and suspected
binding sites of teixobactin to its cellular targets—the bacterial
cell wall precursors : lipid II (Figure 1 B) and lipid III. To date, the
mechanism of action of teixobactin has not been fully un-
covered, although evidence suggests amyloid-like aggregation
after binding to lipid II might play a significant role in the anti-
microbial activity.[15]
To further understand the mechanisms of teixobactin bind-
ing, we embarked on studies investigating the relationship be-
tween teixobactin and several synthetic analogues (Figure 1 A)
and that of lipid II variants using isothermal titration calorime-
try (ITC), which has been successfully used to study lipid II
interactions with other antimicrobial peptides.[17, 18] Due to the
rarity of the allo-End residue and solubility issues associated
with teixobactin (1), more readily accessible and water-soluble
analogues were chosen for this study. Lipid II binding by native
teixobactin, as well as four synthetic analogues, was initially
tested against the Gram-positive lipid II variant, which was syn-
thesized as previously reported[19] and contains lysine at the 3-
position of the pentapeptide (Figure 1 A), the results of which
are provided in Table 1. Teixobactin analogue 3, in which the
enduracididine was replaced by the lysine, binds Gram-positive
lipid II as strongly as native teixobactin (1), with Kd values of
0.60 and 0.43 mm, respectively. Notably, ITC was also performed
with teixobactin and Gram-positive lipid II in large unilammelar
vesicles, and these trials provided analogous results, with a Kd
value of 0.10 mm (Table S1 in the Supporting Information). In
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contrast, analogue 2, where arginine has replaced the native
enduracididine residue, binds lipid II with a tenfold weaker af-
finity than parent natural product (Kd 4.1 mm). The Gram-nega-
tive lipid II binding of the other two analogues investigated
(with Ser to Lys substitution at position 3 or d-Gln to d-Lys at
position 4 of the linear tail of teixobactin) was approximately
100-fold weaker, with dissociation constants of 63 and 38 mm
for analogues 4 and 5, respectively. These analogues were
designed with the results from the Albericio group in mind,
which showed that positions 3 and 4 Lys substitutions are tol-
erated and activity is largely maintained.[20]
Building upon these results with the Gram-positive lipid II,
we next turned our attention to the Gram-negative variant of
lipid II containing diaminopimelic acid (DAP) in place of lysine
in the pentapeptide motif (7). This extra carboxylic acid may
play a role in binding by providing an additional hydrogen
bond acceptor and donor. Specifically, teixobactin analogues 2
and 3, which both contain a free amino group, were found to
be the tightest Gram-negative lipid II binders with Kd values of
0.06 and 0.90 mm, respectively. Notably, native teixobactin
binds to Gram-negative lipid II with a weaker affinity, with a
measured Kd value of 1.36 mm. This was similar to the dissocia-
tion constants measured for analogues 4 and 5 (Kd values of
1.68 and 2.30 mm, respectively).
To further probe the key binding interactions of teixobactin,
the analogues were also assessed against a series of synthetic
truncated lipid II analogues (Figure S1 and Table S1). In line
with previously reported results,[5] we found that phospholi-
pids bearing an unsubstituted pyrophosphate bind with teixo-
bactin nearly as well as the full-length Gram-positive lipid II
molecule. Binding studies with native teixobactin and unde-
caprenyl pyrophosphate (C55-PP, 13) revealed a Kd value of
0.82 mm. By comparison, teixobactin binding to monophos-
phate lipids was significantly decreased with Kd values of
7.69 mm for undecaprenyl phosphate (C55-P, 10) and 11.26 mm
for the Z,Z-farnesyl phosphate (Z,Z-C15-P, 8). The pyrophosphate
moiety is suspected to form intermolecular hydrogen bonds
with the macrocycle of teixobactin, an evidently important
interaction required for recognition and binding.[15] Attempts
were made to elucidate the binding motifs of these inter-
actions (pyrophosphorylated lipids with native teixobactin) by
using NMR spectroscopy. However, these experiments were
not feasible in solution-phase as a compatible solvent for both
the lipid and the peptide were not found, leading to solubility
issues. Similar interactions were investigated using solid-phase
NMR and were reported just last year.[15]
Given that teixobactin and its analogues were found to bind
readily to the Gram-negative lipid II variant, yet do not possess
strong antimicrobial activity against the Gram-negative organ-
isms, we next sought to explore whether the combination of
teixobactin with known Gram-negative outer membrane-dis-
Figure 1. Structures of A) teixobactin and its structural analogues under study and B) native lipid II variants of Gram-positive and Gram-negative bacteria.
Table 1. Binding parameter Kd [mm] of teixobactin analogues and lipid
II.[a]
Compound Native Arg10 Lys10 Lys3Lys10 d-Lys4Lys10
(1) (2) (3) (4) (5)
Lys-lipid II (6) 0.43 4.13 0.60 63.01 37.86
DAP-lipid II (7) 1.36 0.06 0.90 1.68 2.30
[a] Values are the average dissociation constants obtained from isother-
mal calorimetry trials; deviation range: 27.17–1.7 nm.
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rupting peptides would lead to improved antimicrobial activity.
This strategy has proved successful for other molecules with a
limited spectrum of activity against Gram-negative organ-
isms,[21, 22] whereby the minimum inhibitory concentration (MIC)
of the antimicrobial of interest is lowered when combined
with outer membrane-disrupting peptides. To this end, two
peptides, unacylated tridecaptin (H-TriA1) and polymyxin B
nonapeptide (PMBN; Figure S3), were evaluated for the ability
to synergize with teixobactin. For the synergistic assay, the
same panel of teixobactin analogues were combined with H-
TriA1 or PMBN in increasing concentrations up to 12.5 and
30 mg mL@1, respectively. In the presence of the outer mem-
brane-disrupting peptides, nearly all strains tested were shown
to be more sensitive toward the administered teixobactin
(Table 2). Of the strains tested, Salmonella enterica ATCC 13311
proved to be most sensitive to teixobactin in combination
with H-TriA1. Most notable were the 125- and 1024-fold de-
creases in MIC observed for native teixobactin and analogue 2,
respectively, when tested in combination with H-TriA1 at a con-
centration of 12.5 mg mL@1. Interestingly, the synergy observed
for teixobactin and its analogues with PMBN was much less
pronounced with MIC enhancements not exceeding an eight-
fold reduction at the highest PMBN concentrations tested
(30 mg mL@1). Previous work has revealed that H-TriA1 interacts
with lipopolysaccharides in a concentration-dependent manner
while PMBN reaches a maximum concentration, or saturation
point, after which additional PMBN does not bind to the same
cell.[23] A more extensive data set and other MICs results can
be found in Table S2.
In summary, through a series of thermodynamic measure-
ments, it was found that teixobactin and a series of synthetic
analogues bind both Gram-positive and Gram-negative var-
iants of lipid II with high affinity. Furthermore, in the presence
of Gram-negative outer membrane-disrupting peptides, such
as unacylated tridecaptin and polymyxin B nonapeptide, the
activity of teixobactin against Gram-negative organisms can be
dramatically enhanced. Notably, this can effectively lower the
concentration of teixobactin needed to elicit antimicrobial af-
fects against Gram-negative organisms while at concentrations
below the solubility limitations of the peptide and its ana-
logues. This information provides additional insight toward a
more complete understanding of the mechanistic details in-
volved in the mode of action of teixobactin through the bind-
ing of lipid. These findings will be valuable for the future
design of new antibiotic leads based on the natural product
teixobactin.
Experimental Section
Minimum inhibitory concentration determination: The MICs pre-
sented here were determined using microbroth dilution assays fol-
lowing the protocol of the Clinical and Standards Laboratory Insti-
tute.[24] Antimicrobial peptides were dissolved in MHB and serial di-
lutions were made across a 96-well plate. Each plate was inoculat-
ed with the organism in question to reach a final inoculum of 5 V
105 colony forming units per mL. Using OD600 readings normalized
to a blank control, MICs were recorded as the lowest concentration
at which no growth was detected after a 24 h, or 48 h for K. pneu-
moniae, incubation.
Synergistic bioassays with outer membrane-disrupting peptides:
Synergistic bioassays were conducted using an adjusted micro-
broth dilution assay mentioned above to observe the effects of
unacylated tridecaptin (H-TriA1) and polymyxin B nonapeptide
(PMBN). Serial dilutions of the teixobactin analogues were per-
formed across five rows of a 96-well plate. To each row, 50 mL were
added of (A) sterile water, (B–E) increasing concentrations of outer
membrane-disrupting peptides. H-TriA1 was added in 1.56, 3.13,
6.25, 12.5 mg mL@1 to rows (B–E), respectively; PMBN was added at
concentrations of 3.25, 7.5, 15, 30 mg mL@1 to rows (B–E), respec-
tively. The last row (F) contained the highest concentration of
outer membrane-disrupting peptide without teixobactin. Each well
was inoculated with the desired organism and the plates were
incubated at the designated temperature. The MICs were deter-
mined using OD600 readings.
Isothermal titration calorimetry using free in-solution lipids and
peptides: Microcalorimetric experiments were performed on an
MCS isothermal titration calorimeter (Microcal, Northampton, MA,
USA) at 25 8C. The lipid variant solution was prepared at a concen-
tration of 100 mm in Tris buffer (10 mm Tris·HCl, 150 mm NaCl,
pH 6.5) and the teixobactin and teixobactin analogue solutions
were prepared to 10 mm in the same Tris buffer. Samples were de-
gassed by stirring under vacuum at 20 8C for 8 min immediately
before use. The lipid solution was titrated into teixobactin solution
Table 2. Minimum inhibitory concentrations [mg mL@1] of teixobactin ana-
logues.[a]
Organism Teixobactin Alone H-TriA1 PMBN
E. coli
ATCC 25822
Native 22.5 0.70 5.63
Arg10 90 22.5 45
Lys10 45 22.5 22.5
Lys3Lys10 22.5 1.41 2.81
d-Lys4Lys10 22.5 11.3 22.5
E. coli
DH5a
Native 22.5 2.81 5.63
Arg10 45 11.3 22.5
Lys10 45 5.63 11.3
Lys3Lys10 22.5 1.41 2.81
d-Lys4Lys10 22.5 11.3 22.5
S. enterica
ATCC 13311
Native 22.5 0.18 11.3
Arg10 90 0.09 22.5
Lys10 45 0.09 22.5
Lys3Lys10 22.5 0.70 11.3
d-Lys4Lys10 22.5 1.41 5.63
S. enterica
ATCC 23564
Native 45 11.3 5.63
Arg10 n.o.[b] 11.3 22.5
Lys10 90 22.5 22.5
Lys3Lys10 22.5 5.63 11.3
d-Lys4Lys10 22.5 5.63 5.63
Klebsiella pneumoniae
ATCC 13883
native 45 5.63 11.3
Arg10 45 1.41 22.5
Lys10 45 2.81 45
Lys3Lys10 45 1.41 2.81
d-Lys4Lys10 45 1.41 45
[a] MIC values obtained for each teixobactin analogue alone are listed, as
well as synergistic treatment with H-TriA1 (12.5 mg mL
@1) and PMBN
(30 mg mL@1) for a selection of Gram-negative bacteria. [b] MIC not ob-
served at the highest soluble concentration of teixobactin tested.
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using the following conditions: T = 25 8C, reference power =
25 mCal s@1, syringe-stirring speed = 300 rpm, number of injec-
tions = 29, injection volume = 10 mL, initial delay = 60 s, and time
between injections = 300 s. The change in heat rate during each in-
jection was registered in real time and raw data were processed
using the software provided with the instrument, Origin 7. Control
experiments were performed using a similar protocol in which the
buffer solution was titrated into buffer solution and lipid II was
titrated into buffer solution. Each experiment and control was per-
formed in triplicate.
Isothermal titration calorimetry with symmetric incorporation of
lipid II into artificial large unilammeral vesicles (LUVs): Dioleoyl
phosphatidylcholine (DOPC) LUVs (0.2 mm) as a control or 1 mol %
Gram-positive lipid II containing DOPC LUVs were prepared as pre-
viously described.[18] LUV binding experiments were performed
using a MicroCal PEAQ-ITC Automated microcalorimeter (Malvern).
The samples are equilibrated to 25 8C prior to the measurement.
The vesicle suspension of 0.1 mm Gram-positive lipid II, 10 mm
DOPC in 50 mm Tris, pH 7.5 was titrated into a freshly made
solution of 20 mm teixobactin in the same buffer. The titration is
conducted under the following conditions: T = 25 8C, reference
power = 5 mCal s@1, syringe-stirring speed = 1000 rpm, number of
injections = 25, injection volume= 1.5 mL, and time between injec-
tions = 180 s. The calorimetric data obtained were analyzed by
using MicroCal PEAQ-ITC Analysis Software Version 1.20. Experi-
ments and controls were performed in triplicate.
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